Recommendations for probiotic use - 2011 update

Journal of Clinical Gastroenterology

Volumn 45, Issue SUPPL. 3, 2011, Pages

  Floch, Martin H ^a   Walker, W Allan ^b   Madsen, Karen ^c   Sanders, Mary Ellen ^d   Macfarlane, George T ^e   Flint, Harry J ^f   Dieleman, Levinus A ^c   Ringel, Yehuda ^g   Guandalini, Stefano ^h   Kelly, Ciaran P ⁱ   Brandt, Lawrence J ^j  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d DAIRY AND FOOD CULTURE TECHNOLOGIES   (United States)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

^f ROWETT RESEARCH INSTITUTE   (United Kingdom)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

more..

Author keywords

diarrhea; probiotics; recommendations

Indexed keywords

PROBIOTIC AGENT;

CARDIOVASCULAR RISK; CLOSTRIDIUM DIFFICILE INFECTION; CONFERENCE PAPER; DIARRHEA; ENTERITIS; HUMAN; IMMUNE RESPONSE; INTESTINE FLORA; IRRITABLE COLON; MICROFLORA; MICROORGANISM; NECROTIZING ENTEROCOLITIS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PUBLICATION;

DIARRHEA; ENEMA; ENTEROCOLITIS, NECROTIZING; FECES; GASTROINTESTINAL DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; PROBIOTICS;

EID: 80054098741     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318230928b     Document Type: Conference Paper

References (48)

1. Floch MH, Madsen KK, Jenkins DJA, et al. Recommendations for probiotic use. J Clin Gastroenterol. 2006;40:275-278.
2. Floch MH, Walker WA, Guandalini S, et al. Recommendations for probiotic use-2008. J Clin Gastroenterol. 2008;42:S104-S108.
3. Floch MH, Walker WA, Madsen K, et al. Recommendations for probiotic use-2011 Update. J Clin Gastroenterol. 2011;45.
4. Madsen K. Interactions between microbes and the gut epithelium. J Clin Gastroenterol. 2011;45:S111-S114.
5. Sanders ME. Impact of probiotics on colonizing microbiota of the gut. J Clin Gastroenterol. 2011;45:S115-S119.
6. Macfarlane G, Macfarlane S. Fermentation in the Human Large Intestine; Its Physiologic Consequences, and the Potential Contribution of Prebiotics. J Clin Gastroenterol. 2011;45:S120-S127.
7. Flint HJ. Obesity and the microbiome. J Clin Gastroenterol. 2011;45:S128-S132.
8. Meijer BJ, Dieleman LA. Probiotics in the treatment of human inflammatory bowel diseases: update 2011. J Clin Gastroenterol. 2011;45:S139-S144.
9. Ringel Y, Ringel-Kulka T. The rationale and clinical effectiveness of probiotics in irritable bowel syndrome. J Clin Gastroenterol. 2011;45:S145-S148.
10. Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol. 2011;45:S149-S153.
11. Na X, Kelly C. Probiotics in Clostridium difficile infection. J Clin Gastroenterol. 2011;45:S154-S158.
12. Evidence-based medicine. In Wikipedia. Retrieved June 26, 2011 from http://en. wikipedia.org/wiki/Evidence-based-medicine.
13. Ganguli K, Walker WA. Probiotics in the prevention of necrotizing enterocolitis. J Clin Gastroenterol. 2011;45:S133-S138.
14. Brandt LJ, Reddy SS. Fecal microbiotic transplantation for recurrent Clostridium difficile infection. J Clin Gastroenterol. 2011;45:S159-S167.
15. Szujewsku H, Skorka A, Dylag M. Meta-analysis. Saccharomyces boulardii for treating acute diarrhea in children. Aliment Pharmacol Ther. 2007;25:257-264.
16. Guandalini S, Pensabene I, Zikri MH, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multi-center European Trial. J Pediatr Gastroenterol Nutr. 2000;30:54-60.
17. Shornikova AV, Casus I, Isolauri E, et al. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr. 1997;24:399-404.
18. Guandalini S. Probiotics for children with diarrhea: an update. J Clin Gastroenterol. 2008;42:S53-S57.
19. Surawicz CM. Role of probiotics in antibiotic associated diarrhea, Clostridium difficile associated diarrhea and recurrent Clostridium difficile diarrhea. J Clin Gastroenterol. 2008;42:S64-S70.
20. Doron S, Hibberd P, Gorbach SL. Probiotics for prevention of antibiotic-associated diarrhea. J Clin Gastroenterol. 2008;42:S58-S63.
21. Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhea associated with antibiotics: randomized double blind placebo controlled trial. BMJ. 2007;355:80.
22. Katz JA. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. J Clin Gastroenterol. 2006;40:249-255.
23. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305-309.
24. Gionchetti P, Rizzello F, Helwig U, et al. Prophylactis of pouchitis onset with probiotic therapy: a doubleblind, placebo-controlled trial. Gastroenterology. 2003;124:1202-1209.
25. Mimura T, Rizzello F, Helwig U, et al. Once-daily high-dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108-114.
26. Gionchetti P, Rizzello F, Morselli C, et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum. 2007;50:2075-2084.
27. Rembacken FJ, Snelling AM, Hawkey PM, et al. Nonpathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet. 1999;354:635-639.
28. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005;100:1539-1546.
29. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437-443.
30. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617-1623.
31. Malchow HA. Crohn's disease and Escherichia coli: a new approach in therapy to maintain remission of colonic Crohn's disease. J Clin Gastroenterol. 1997;25:653-658.
32. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000;45:1462-1464.
33. Gupta P, Andrew H, Kirschner BS, et al. Is Lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary open-label study. J Pediatr Gastroenterol Nutr. 2000;31:453-457.
34. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium Infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101:1581-1590.
35. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome (IB): symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541-551.
36. Kim JH, Camilleri M, McKenzie S, et al. A randomized controlled trial of a probiotic, VSL#3 on gut transit and symptoms in diarrhea-predominant IBS. Aliment Pharmacol Ther. 2003;17:895-904.
37. Kim JH, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of probiotic combination VSL#3 and placebo in IBS with bloating. Neurogastroenterol Motil. 2005;17:687-696.
38. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-172 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized double-blind, controlled trial. Aliment Pharmacol Ther. 2007;26:475-486.
39. Niedzielin K, Kordecki H, Birkenfeld B, et al. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299 V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2001;13:1143-1147.
40. Isolauri E, Joensuu J, Suomalainen H, et al. Improved immunogenicity of oral DxRRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine. 1995;13:310-312.
41. Isolauri E, Salminen S. Probiotics: use in allergic disorders. J Clin Gastroenterol. 2008;42:S91-S96.
42. Delia P, Sansotta G, Donato V, et al. Prevention of radiationinduced diarrhea with the use of VLS#3, a new highpotency probiotic preparation. Am J Gastroenterol. 2002;97:2150-2152.
43. Salminen E, Eloman I, Minkkinen J, et al. Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. Clin Radiol. 1988;39:435-437.
44. Hilton F, Isenberg HD, Alperstein P, et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Am Intern Med. 1992;116:353-357.
45. Anukam K, Osazuwa E, Ahonkhai I, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect. 2006;8:2772-2776.
46. Anukam KC, Osazuwu E, Osemen GI, et al. Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect. 2006;8:2772-2776.
47. Lin HC, Chyong-Hsin H, Hsiu-Lin C, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth rate preterm infants: a multicenter, randomized, controlled trial. Pediatrics. 2008;122:693-700.
48. Guandalini S, Magazzu G, Chiaro A, et al. VSL#3 improves symptoms in children with irritable bowel syndrome: an international, randomized, placebo-controlled, double-blinded, cross-over study. J Pediatr Gastroenterol Nutr. 2010;51:24-30.